Thalidomide: mechanisms of action.

Int Rev Immunol

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Published: August 2008

The classification of thalidomide as an orphan drug with anti-inflammatory actions has led to its off-label use in conditions refractory to other medications. Although the observed clinical effects of thalidomide suggest it to have immunomodulatory capabilities, the mechanism of action is unclear. Here we review both the positive and negative studies of thalidomide at the bench in order to improve our understanding of the possible mechanisms of this drug in treating a variety of diseases at the bedside. Studies on the effects of thalidomide on the innate and adaptive immune system as well as tumorigenesis and angiogenesis are discussed.

Download full-text PDF

Source
http://dx.doi.org/10.1080/08830180801911339DOI Listing

Publication Analysis

Top Keywords

effects thalidomide
8
thalidomide
5
thalidomide mechanisms
4
mechanisms action
4
action classification
4
classification thalidomide
4
thalidomide orphan
4
orphan drug
4
drug anti-inflammatory
4
anti-inflammatory actions
4

Similar Publications

Congenital intracranial hemangiomas are rare benign vascular tumors that develop before birth. Although various treatments, including surgery, steroids, interferon-α, thalidomide, bevacizumab, or propranolol, have been reported, no standard therapy has been established. We report the case of a neonate with congenital intracranial hemangioma and central nervous system symptoms requiring therapeutic intervention.

View Article and Find Full Text PDF

Inhalation of crystalline silica particles causes silicosis, which is a severe inflammatory lung disease that is associated with granulomatous and fibrotic responses. We investigated whether silica-induced silicosis might promote airway hyperreactivity (AHR) and the role of TNF-α and thalidomide in this process. Mice received an intranasal instillation of silica particles (1.

View Article and Find Full Text PDF

Objective: Combining immune checkpoint inhibitors and antiangiogenic agents offers a promising strategy to counteract the cooperative promotion of solid tumor growth by immune checkpoints and intratumoral angiogenesis.

Methods: We investigated the potential of thalidomide (THD) and anti-PD-1 antibody (PD-1 mAb) in suppressing tumor growth, enhancing immunity, and inhibiting angiogenesis.

Results: THD exhibited regulatory effects on PD-1 in CD4+ T cells and PD-L1 in cancer cells, along with tumor growth inhibition in A549 and Lewis lung carcinoma (LLC) cell lines.

View Article and Find Full Text PDF

Radiation therapy is widely recognized as an efficacious modality for treating neoplasms located within the craniofacial region. Nevertheless, this approach is not devoid of risks, predominantly concerning potential harm to the neural structures. Adverse effects may encompass focal cerebral necrosis, cognitive function compromise, cerebrovascular pathology, spinal cord injury, and detriment to the neural fibers constituting the brachial plexus.

View Article and Find Full Text PDF
Article Synopsis
  • Multiple myeloma (MM) is the second most prevalent blood cancer worldwide, traditionally viewed as aggressive and deadly.
  • Recent advancements in treatment, such as proteasome inhibitors, monoclonal antibodies, immunomodulators, and corticosteroids, have improved patient outcomes significantly.
  • Due to innovative combination therapies and ongoing research, there is growing optimism for future treatments, aiming to make MM more manageable and potentially curable.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!